Drug Database
Back to search

France· FR:66376626

VYNDAQEL 20 mg, capsule molle

A medicinal product containing tafamidis méglumine, registered in France by PFIZER EUROPE MA EEIG (BELGIQUE), on the national reimbursement list.

Reimbursed in France (Assurance maladie)

Checked against Base de données publique des médicaments — BDPM (France) on

Informational only — not a medical device.

SOURCE REGISTER · FRBase de données publique des médicament…normalisedVYNDAQEL 20 mg, capsule molleATC—REGISTER NO.FR:66376626PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about tafamidis méglumineAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

The record

At a glance

Base de données publique des médicaments — BDPM (France)
Active substance
TAFAMIDIS MÉGLUMINE
Manufacturer
PFIZER EUROPE MA EEIG (BELGIQUE)
Country
France (FR)
ATC code
—
Reimbursed
Yes
Source register
Base de données publique des médicaments — BDPM (France)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • cip13
    3400921824599
    plaquettes PVC polyamide aluminium PVC-Aluminium de 30 x 1 capsules (conditionnement unitaire)
    EUR 3.96

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Tafamidis méglumine in 5 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All tafamidis méglumine products

Authorised across Europe · EMA

The same active substance is authorised in 7 EEA countries. Names it is sold under:

  • Belgium · Tafamidis Ab
  • Spain · Tafamidis Aurovitas, Tafamidis Goibela
  • Iceland · Vyndaqel
  • Liechtenstein · Vyndaqel
  • Luxembourg · Tafamidis Ab
  • Norway · Vyndaqel
  • Portugal · Tafamidis Generis, Tafamidis Generis Phar

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/61233d53-9101-4317-9923-d958df096137
GET /v1/drugs/61233d53-9101-4317-9923-d958df096137?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "cis": "66376626",
  "date_amm": "2011-11-16",
  "type_amm": "Procédure centralisée",
  "numero_ue": "EU/1/11/717",
  "substance": "TAFAMIDIS MÉGLUMINE",
  "statut_amm": "Autorisation active",
  "statut_bdm": null,
  "forme_pharmaceutique": "capsule molle",
  "voies_administration": "orale",
  "etat_commercialisation": "Commercialisée",
  "surveillance_renforcee": "Oui"
}
API referenceMCP serverPlans

See everything about tafamidis méglumine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console